transthyretin amyloidosis

First-of-its-kind Intellia data suggest CRISPR drug could be given more than once
BioPharma Dive
Wed, 06/26/24 - 10:00 am
Intellia Therapeutics
CRISPR
gene editing
transthyretin amyloidosis
Intellia presses forward with new results for pioneering CRISPR drug
BioPharma Dive
Mon, 02/28/22 - 11:46 pm
Intellia Therapeutics
CRISPR
transthyretin amyloidosis
BridgeBio says trial for acoramidis in transthyretin amyloidosis did not meet main goal
Seeking Alpha
Mon, 12/27/21 - 11:16 am
BridgeBio
acoramidis
clinical trials
transthyretin amyloidosis
AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug
BioPharma Dive
Tue, 12/7/21 - 10:48 am
AstraZeneca
Ionis Pharmaceuticals
transthyretin amyloidosis
eplontersen
8 key clinical trials to watch for the rest of 2021
BioPharma Dive
Mon, 06/21/21 - 11:11 am
clinical trials
Merck
Ridgeback Biotherapeutics
COVID-19
Intellia Therapeutics
transthyretin amyloidosis
Arcus Biosciences
Gilead Sciences
lung cancer
Sanofi
GSK
vaccines
uniQure
Huntington's disease
Mirati Therapeutics
gene editing
Seres Therapeutics
ulcerative colitis
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel
Fierce Biotech
Tue, 02/18/20 - 08:30 pm
Europe
Pfizer
transthyretin amyloidosis
ATTR-CM
Vyndaqel
Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms
Xconomy
Thu, 03/15/18 - 11:09 am
Ionis Pharmaceuticals
Akcea
Alnylam
transthyretin amyloidosis
inotersen
IONIS-TTR-Lrx
Glaxo Shells Out $7.5 Million for Milestone Payment to Isis
Yahoo/Zacks
Wed, 02/27/13 - 11:33 am
GSK
Isis Pharmaceuticals
ISIS-TTRRx
transthyretin amyloidosis
Isis Pharmaceuticals Launches Trial, Hits Milestone
Motley Fool
Fri, 02/22/13 - 10:39 am
Isis Pharmaceuticals
ISIS-TTR
antisense
GSK
transthyretin amyloidosis
TTR-mediated amyloidosis